Chitosan nanoparticles: A versatile platform for biomedical applications
The challenge of developing novel pharmacological therapies for nonalcoholic steatohepatitis
GHK-Cu has an established safety record spanning more than five decades of both topical cosmetic use and controlled research application
For example, use of PSMA-PET, which is already standard for staging, restaging, and eligibility assessment for PSMA-targeted radioligand therapy, can be extended to PSMA-targeting ADCs 253,254
However, retatrutide remains investigational and is not yet approved in the UK or United States, with regulatory submission still pending and approval not anticipated before 2027 at the earliest
We talked about the red flags: unusual varicose veins, pelvic or leg heaviness, swelling, bladder symptoms, and so much more